NAD+ is not a peptide
Nicotinamide adenine dinucleotide (NAD+) is a nucleotide-derived cellular coenzyme, not a peptide. It participates in redox reactions and enzyme signaling. Essential biology does not by itself show that intravenous NAD+ improves energy, cognition, addiction, longevity, recovery, or wellness.
Direct IV evidence is extremely limited
A 2019 pilot followed the NAD+ metabolome during a six-hour intravenous infusion; it was designed around metabolism and tolerability, not controlled proof of clinical benefit.[1] A 2026 retrospective real-world pilot compared infusion tolerability rather than establishing efficacy.[2] Human studies of oral precursors such as nicotinamide riboside or nicotinamide mononucleotide test different substances and routes and cannot validate IV NAD+ clinic claims.
Safety and quality gaps
Published IV studies are too small to define uncommon events, long-term outcomes, interactions, pregnancy use, or benefits. Intravenous administration also adds line, infection, contamination, dosing, and infusion-reaction risks. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[3]
Regulatory status
There is no FDA-approved IV NAD+ product for anti-aging, wellness, fatigue, cognition, addiction treatment, or recovery. Teloryx does not publish an infusion dose, rate, schedule, or preparation recipe.